The artificial intelligence (AI) modalities CINA-iPE and CINA-ASPECTS may facilitate improved detection of incidental pulmonary embolism and stroke evaluation, respectively, based on computed tomography (CT) scans.
The Food and Drug Administration (FDA) has granted 510(k) clearance to the artificial intelligence (AI)-powered CINA-ASPECTS, which may enhance the evaluation of stroke severity, and the AI-enabled CINA-IPE, which is geared toward bolstering the detection of incidental pulmonary embolism (PE).
Based off brain non-contrast computed tomography (NCCT) images, the CINA-ASPECTS modality provides heat mapping probabilities of sulcal effacement and hypodensity, identifies infarcted regions and offers automated ASPECT scoring for stroke severity, according to Avicenna.AI, the developer of CINA-ASPECTS.
"The validations and multi-reader-multi-case studies we conducted highlighted that CINA-ASPECTS not only obtained outstanding standalone performance, but also demonstrated that its adjunctive use significantly improved clinicians' accuracy in the assessment of ASPECTS regions, compared to the conventional use of NCCT images alone," added Yasmina Chaibi, a clinical affairs manager for Avicenna.AI.
Avicenna.AI said the CINA-iPE modality, reportedly validated on 381 CT scans from 39 different CT scanner models, may facilitate timely triage with its strong sensitivity and specificity for the diagnosis of incidental PE.
Multicenter CT Study Shows Benefits of Emerging Diagnostic Model for Clear Cell Renal Cell Carcinoma
May 15th 2024Combining clinical and CT features, adjunctive use of a classification and regression tree (CART) diagnostic model demonstrated AUCs for detecting clear cell renal cell carcinoma (ccRCC) that were 15 to 22 percent higher than unassisted radiologist assessments.
MRI-Based Deep Learning Algorithm Shows Comparable Detection of csPCa to Radiologists
May 8th 2024In a study involving over 1,000 visible prostate lesions on biparametric MRI, a deep learning algorithm detected 96 percent of clinically significant prostate cancer (csPCa) in comparison to a 98 percent detection rate for an expert genitourinary radiologist.